Changes in CD4+ T cells associated with autoimmune diseases
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
List view / Grid view
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
Disruptions in TP53 and RB1 are key influencers that cause changes in the risk of mutations across chromosomes.
Researchers found that ANG in its mutated form slows stem cell differentiation, resulting in neurodevelopmental defects in adult nerve cells.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
Using phosphoproteomics, the calcium channel Cav2.3 was found as a target to treat a type of genetic epilepsy, CDKL5 deficiency disorder.
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
Download this exclusive content focusing on new RNA editing technology, the challenges and opportunities presented and the potential of RNA-based therapeutics.
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
Researchers have completely decoded the human Y chromosome, which may result in more effective treatment for digestive disorders.
Analysis of cells shows many regions in DNA are differentially activated or inactivated in a cancer-specific manner.
A $1.2 million grant has been given to observe how Z-RNA is formed and explore its benefits for various diseases.
Researchers gain insight into how brain tissue is impacted differently by genetic problems compared to the rest of the body.
New MGH study finds that macrophages and macrophage-produced proteins contribute to heartbeat irregularities, thus targeting these cells can aid atrial fibrillation treatment.
HGPS mouse models were used to test the hypothesis that the accelerated aging typical of progeroid mice is associated with reduced hepatic H2S production.
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.